Do thiazolidinediones increase the risk of congestive heart failure and cardiovascular death?

Nature Clinical Practice Endocrinology and Metabolism

Volumn 4, Issue 5, 2008, Pages 260-261

  Scheen, André J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Congestive heart failure; Diabetes mellitus; Pioglitazone; Rosiglitazone; Thiazolidinedione

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; PIOGLITAZONE; ROSIGLITAZONE;

AUTHOR; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; COCHRANE LIBRARY; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; EMBASE; FEMALE; FOLLOW UP; HEALTH CARE ORGANIZATION; HEART DEATH; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; MALE; MEDLINE; META ANALYSIS; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OUTCOME ASSESSMENT; POPULATION SIZE; PRIORITY JOURNAL; RISK FACTOR; SYSTEMATIC REVIEW;

EID: 42449118000     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet0781     Document Type: Note

References (5)

1. Home PD et al. (2007) Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med 357: 28-38
2. Erdmann E et al. (2007) Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 30: 2773-2778
3. Nathan DM et al. (2008) Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: update regarding the thiazolidinediones. Diabetologia 51: 8-11
4. The DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) Trial Investigators (2006) Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368: 1096-1105
5. Bolen S et al. (2007) Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 147: 386-399